What changed from existing technology?
This study discusses how new drug delivery systems can more accurately target cancer cells, improving treatment effectiveness and reducing side effects compared to traditional chemotherapy.
The study highlights the shift from passive tumor accumulation using the enhanced permeability and retention effect to more precise, actively targeted drug delivery systems that improve therapeutic outcomes.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
CONVENTIONAL APPROACHES TO PRECISION MEDICINE. Cancer remains one of the major causes of morbidity and mortality worldwide, despite substantial advances
Abstract ↗OpenAlex author affiliations: Avanti (United Kingdom)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
These targeted drug delivery systems may improve cancer treatment by reducing systemic toxicity and increasing drug concentration in tumor tissues.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchADVANCED TARGETED DRUG DELIVERY SYSTEMS FOR CANCER THERAPY: FROM CONVENTIONAL APPROACHES TO PRECISION MEDICINEZenodo (CERN European Organization for Nuclear Research) · Published 2026-08-29 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.